The UK’s National Health Service (NHS) and the company leading drug development in cystic fibrosis (CF) remain at loggerheads.
Both sides claim that the pricing mechanisms being employed by the other are not viable in a situation has led to UK politicians, patients and charities expressing their despair.
"The scale of parliamentary engagement in this debate echoes and amplifies the CF community’s sense of urgency on access to new Vertex medicines"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze